产品说明 一般描述 Suramin is an antiparasitic drug, which blocks endothelial cell proliferation and increases tyrosine phosphorylation of many signalling proteins. It is associated with urticaria, paresthesias, vomiting and neurologic toxicity. Suramin is used to treat trypanosomiasis and onchocerciasis. It functions as an inhibitor of heparanase and also exhibits anti-AIDS (acquired immunodeficiency syndrome) property. 应用 Suramin sodium salt has been used: - as a potent blocker of rat P2Y2 purinergic receptor
- to study its effects on short circuit current (Isc) across strial marginal cells
- to show its effects on initial burst of glial activity
- to assess its neuroprotective potential in rats
- as a purinoceptor inhibitor, to explore the mechanism of action of extracellular adenosine triphosphate (eATP)
包装 100, 500 mg in poly bottle 生化/生理作用 Suramin is a polysulfonated naphthylurea anticancer agent that inhibits tumor cell proliferation. It inhibits the activity of topoisomerase II by blocking the binding of the enzyme to DNA. It′s antiangiogenic activity may be related to its ability to bind to and inhibit the activity of several growth factors, including FGFa, FGFb, and PGDF. It uncouples G-proteins from receptors. It is an broad spectrum antagonist at P2X and P2Y purinergic receptors. Suramin has well documented antiprotozoal and anthelmintic activity. 基本信息 | 经验(实验)分子式 | C51H34N6Na6O23S6 | | 分子量 | 1429.17 | | Beilstein | 3694087 | | EC 号 | 204-949-3 | | MDL编号 | MFCD00210217 | | PubChem化学物质编号 | 24277738 | | NACRES | NA.25 |
产品性质 | 质量水平 | 200 | | 测定 | ≥98% (TLC) | | 溶解性 | H2O: >10 mg/mL | | SMILES string | [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1ccc(cc1NC(=O)c2cccc(NC(=O)Nc3cccc(c3)C(=O)Nc4cc(ccc4C)C(=O)Nc5ccc(c6cc(cc(c56)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)c2)C(=O)Nc7ccc(c8cc(cc(c78)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O | | InChI | 1S/C51H40N6O23S6.6Na/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80;;;;;;/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80);;;;;;/q;6*+1/p-6 | | InChI key | VAPNKLKDKUDFHK-UHFFFAOYSA-H | | Gene Information | human ... EGF(1950), FGF1(2246), P2RX1(5023), P2RY1(5028), PDGFA(5154), PLD1(5337) |
安全信息 | 储存分类代码 | 11 - Combustible Solids | | WGK | WGK 3 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | Eyeshields, Gloves, type N95 (US) |
|
产品说明 一般描述 An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids.
A reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of Gα-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids. 包装 50 mg in Plastic ampoule 生化/生理作用 Primary Target
protein tyrosine phosphatases
Target IC50: 15 µM against phospholipase D
Product does not compete with ATP.
Cell permeable: no
Reversible: yes 警告 Toxicity: Standard Handling (A) 重悬 Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C. 其他说明 Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
Denhertog, A., et al. 1992. J. Physiol.454, 591.
Nakajima, M., et al. 1991. J. Biol. Chem.266, 9661.
Wilks, J.W., et al. 1991. Int. J. Radiat. Biol.60, 73.
Huang, R.C., et al. 1990. Mol. Pharmacol.37, 304.
Kopp, R. and Pfeiffer, A. 1990. Cancer Res.50, 6490. 法律信息 CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany 基本信息 | 经验(实验)分子式 | C51H34N6O23S6 · 6Na | | 分子量 | 1429.17 | | MDL编号 | MFCD00210217 |
产品性质 | 质量水平 | 100 | | 测定 | ≥98% (HPLC) | | 形式 | crystalline solid | | manufacturer/tradename | Calbiochem® | | 储存条件 | OK to freeze
desiccated (hygroscopic) | | 颜色 | white | | 溶解性 | water: 5 mg/mL | | 运输 | ambient | | 储存温度 | 2-8℃ | | InChI | 1S/C51H40N6O23S6.6Na/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80;;;;;;/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80);;;;;;/q;6*+1/p-6 | | InChI key | VAPNKLKDKUDFHK-UHFFFAOYSA-H |
安全信息 | 储存分类代码 | 11 - Combustible Solids | | WGK | WGK 3 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
m.cnreagent.com